BMYBristol-Myers SquibbFinished
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
Non-Small Cell Lung Cancer (NSCLC)
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 3
- Patients
- 925 (final count)
- Started
- Oct 8, 2019
- Main results expected
- Mar 22, 2024
- Fully finished
- Nov 26, 2024
- Results posted
- Jul 24, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Arm A Vs Arm C - Progression-Free Survival (PFS) by RECIST 1.1 Per Blinded Independent Central Review (BICR)
Measured over: From randomization untill disease progression or death, whichever occurs first (up to approximately 53 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04026412 · record last updated 2025-07-24 · checked 2026-11-09 15:47 UTC